Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Novel Hydrogel Slows Tumor Growth and Prevents Recurrence

By LabMedica International staff writers
Posted on 06 Mar 2018
A team of cancer researchers developed a novel hydrogel device designed to be injected at the site of a tumor, where it forms a scaffold for sequential release of chemotherapeutic and immunotherapeutic drugs.

Clinical experience has shown that patients with low-immunogenic tumors respond poorly to immune checkpoint blockade (ICB) treatments that target the programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway. More...
On the other hand, patients responding to ICB can experience various unpleasant side effects.

Investigators at the University of North Carolina (Chapel Hill, USA) addressed both of these concerns by maximizing drug access to tumors while minimizing systemic exposure to the drugs. To do this, they engineered a therapeutic scaffold that, when formed in situ, allowed the local release of gemcitabine (GEM) and an anti–PD-L1 blocking antibody (aPDL1) with distinct release kinetics. The scaffold consisted of a reactive oxygen species (ROS)-degradable hydrogel that released therapeutics in a programmed manner within the tumor microenvironment (TME), which contained abundant ROS.

The investigators reported in the February 21, 2018, online edition of the journal Science Translational Medicine that, once in place, the hydrogel first released cytotoxic chemotherapy, which killed some cancer cells before releasing most of an immune checkpoint inhibitor, which then stimulated antitumor immunity. The investigators employed this approach to inhibit growth of primary tumors in mouse models as well as to prevent tumor recurrence after surgery.

"We have created a simple method to use chemotherapy while leveraging the biology of the tumor and our natural defense against foreign invaders to beat back tumor development with limited side effects," said senior author Dr. Zhen Gu, associate professor of biomedical engineering at the University of North Carolina. "We have a lot more work to do before human clinical trials, but we think this approach holds great promise."

"Regarding the potential of this approach, scientists should further investigate the biocompatibility of using the gel scaffold for clinical benefit," said Dr. Gu. "Meanwhile, we will optimize the dosages of combination drugs as well as treatment frequencies."

Related Links:
University of North Carolina


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gastrointestinal Panel
Xpert® GI Panel
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.